HEMOSTEMIX

Production for Revenue

2024

Forward Looking Statements

This presentation contains forward looking statements that reflect management's expectations regarding the future growth and results of operational performance including but not limited to the scientific, financial, competitive and business prospects of Hemostemix Inc. ("Hemostemix" or the "Company"), including "forward-looking statements" and "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information is generally, but not always identified by words such as "may", "would", "could", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "potential", "might", "seek", "budget", "outlook", and other similar expressions. In addition, forward looking statements include, but are not limited to, the Company's assessment of and targets for the stem-cell industry, including the potential opportunities and challenges in the current stem cell industry; matters pertaining to Hemostemix, including its strategy and anticipated and potential transactions and the characteristics thereof; future acquisition opportunities, partnerships, licensing opportunities and joint ventures and its pro forma impact to capitalization following the completion of any of the Company's business opportunities; matters pertaining to the Company's future research and development initiatives including future clinical trials, management's estimated timelines regarding the Company's clinical trials, regulatory approvals for ACP-01 and NCP-01, and many other projected timelines including regulatory approvals of the Company's submission(s); financial modeling matters, including metrics pertaining to anticipated financial and operational performance of operations; and, any matters pertaining to the potential for commercialization of its technology, sources and extent of necessary funding, manufacturing scalability and future business outcomes.

Actual results, performance and achievement(s) could differ materially from that expressed in, or implied by, any forward-looking information in this Presentation and, accordingly, investors should not place undue reliance on any such forward-looking information. Forward-looking information should not be read as guarantees of future performance or results. Forward-looking information and results could differ materially from general business, economic, competitive and regulatory risks now and in the future. As well, results may be inconsistent with general assumptions about the economic environment and stem cell industry environment, the business operations of Hemostemix including that each business will continue to operate in a manner consistent with past practice and pursuant to certain industry expectations and current market conditions.

Any forward-looking statements speak only as of the date on which such statement is made and the Company disclaims any intention or obligation to update or revise any forward-looking information as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to time and it is not possible for management to predict how such factors impact the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking information contained in this Presentation is based on the Company's current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to be correct. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this Presentation is intended to be nor may be construed to be an investment recommendation or a profit forecast.

Currency

Unless otherwise indicated, all values are expressed in Canadian dollars.

Children Rely on our Hearts!

Heart disease is the #1 reason Moms and Dads do not live.

Hemostemix's innovative and patented stem cell technology means more Moms and Dads will be around to see their children and grandchildren grow up.

ACP-01 is the patient's own stem cells. It creates new circulation where the body signals it needs regeneration.

This is a break-through treatment for four types of cardiovascular disease.



HEART:

In three studies of cardiomyopathy, ACP improved mean heart function by 27% as measured by ejection fraction (volume of blood ejected with each heart beat), *Stem Cell Research & Therapy, Nov. 2023.*

CLTI: Saving a Limb is Saving a Life!

Whereas the five-year mortality rate of chronic limb threatening ischemia (CLTI) is 60%, the Universities of Toronto and British Columbia posted that 83% of patients followed in the Phase II trial experienced healing of ulcers, cessation of pain, no major amputation, and no death, for up to 4.5 years.

Production Agreement & Concurrent Equity Placement

CYTOIMMUNE PRODUCTION AGREEMENT

The $1.5 million contract includes a two-year production agreement and $1.1 Million of Revenue. Hemostemix may hire and train its employees to produce at the investor's facility, to be cashflow positive by the end of 2025.

15 YEAR AGREEMENT WITH PUERTO RICO

Act 60 legislation generates 50% cash back of all current and future R&D, + a 15-year 4% tax on profit, + a 20% tax credit for offshore expenses. Renewable for a second 15-year term.

YOUR INVESTMENT OPPORTUNITY

- $0.05 Unit
- 1 Common Share
- 1 Warrant exercisable at $0.12 for two years
- Subject to $0.15 accelerator
- See slide 18 for additional details

Phase II CLTI: Healing of Ulcerating Wounds

In the Phase II CLTI trial, patients with ulcers prior to treatment demonstrated a significant decrease in ulcer size (p=0.001) by 3 months, and decreased amputation and death rate, compared to no significant decrease in the size of ulcers in placebo. Moreover, the rate of amputation (4.8%) and death (4.8%) in the treated was substantially less than placebo, who experienced amputation (25%) and 1 death (12.5%). *Journal of Biomedical Research and Environmental Science, Feb. 2024.*

19 Yrs	**$43M**	**498**
Development	Raised	Treated
9	**7**	**91**
Publications	Clinical Trials	Patents







The Markets are Very Large



Cardiovascular Disease (CVD) doubled from 271 million in 1990 to 620 million in 2021.

At first, our treatment numbers will be modest, focused on HNWIs who can afford it.

However, we can scale to address the larger market opportunity

1 Automated Cell Therapy System (ACTS), a robotic-based production system, produces 240 treatments/month ($144 M/Yr.)

ACTS scales regionally and globally.

Target Markets are Very Large

The global CLTI market was valued at USD $4.02 Billion in 2022. The Ischemic Heart Disease (IHD) drugs market reached USD $6.1 Billion in 2022.

Hemostemix Addressable Market

1/20,000 market penetration in North America and the European Union represents 240 batches/month, and $144 Million in annual revenue. This can be achieved with six clean rooms operating two shifts at 40 batches a month, or one ACTS module producing 240 batches a month.

CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE 2023 TO 2032 (USD BILLION)



Source: www.precedenceresearch.com





The Company projects to be cashflow positive by late 2025, selling 30-40 treatments per month to no-option patients suffering from end-stage critical limb ischemia and heart disease.

ACTS (automated cell therapy system) scales treatments up to 240 per month per pod, once certified.

Filed an application for orphan disease - dilated cardiomyopathy. Once granted, it provides 7 years exclusivity, fee abatement, and grant funding opportunities.

A Multiple Treatments Technology Platform: ACP, NCP, CCP

From the patient's blood, Hemostemix creates ACP, NPC, and CCP

Angiogenic Cell Precursors

Angiogenesis at the site of ischemia. Enhanced migration and repopulation of damaged tissue. Decreased inflammation, anti-apoptotic factors. CLTI & Heart Disease.

Neuronal Cell Precursors

Enhanced secretion of nerve growth factors, Homing of cells to site of injury. Neuro – regenerative!

Small animal study of motor function and neuropathic pain underway at Clemson University.

Cardiomyocyte Cell Precursors

Proposed to create a heart patch in conjunction with an autologous bio scaffold.

Product in Development

Key Process Steps with Treatment on Day 7

ACP (patient's DNA) scales and ships in ready-to-use syringes to physicians globally.



Why Physicians and Patients Like ACP





Historical Event Timeline



Autologous Regenerative Therapeutic Competitors

Company	Indications		Source	Phase		
	Ischemic Heart Disease	Chronic Limb Threatening Ischemia	Chronic Limb Threatening Ischemia	I	II	III
Hemostemix	✓	✓	Peripheral Blood[1,4]		✓	✓
BioCardia	✓		Bone Marrow[2,5]		✓	
Life Cells[3]		✓	Acellular Dermal Matrices[3]		✓	
BioGen Cells		✓	Peripheral Blood[1,6]		✓	

Notes:
1. Simple peripheral blood draw provides patient own unique DNA based source material.
2. Bone marrow derived stem cell source material requires hospitalization which limits scaling of the therapeutic. The procedure is painful and adds risk.
3. Allergen (Abbvie) paid USD $2.9 B cash to Life Cells for its allogenic acellular dermal matrices that serve as scaffolds for tissue repair in surgeries: facial, breast, abdominal and burn reconstructions.
4. Planned closeout of completed Phase II CLTI trial, and commencement of Phase III CLTI trial
5. Results expected in Q4, 2024
6. Recruiting patients

Supply of Treatment Physicians

110 Heart

Invasive Cardiologists

Hemostemix has organized invasive cardiology capacity to treat up to 110 patients/month with cardiologists who have completed 210 regulatory approved ACP heart treatments.

226 CLTI

Phase II Vascular Surgeons

Globally, 236 million suffer from Peripheral Arterial Disease. Approximately 23 million degenerate into CLTI, of which 40% have no-options (9.2 million).

Hemostemix has organized physician capacity to review up to 226 patients/month – 2nd opinion before amputation.

Sales Path to Market – Demand

Sales of ACP for no-option patient treatments will be through clinicians who have regulatory approval to treat.

A sales distribution agreement is in process with 200 stem cell clinics who offer donor cell products. They share one platform for both sales processing and patient records management.

Sales of ACP for heart disease treatments will be through invasive cardiologists who have completed more than 210 such treatments with regulatory approval.

To-date, seven clinical trial sites have agreed to process up to 226 CLTI referrals per month.

The company is pursuing a regional joint venture strategy to produce ACP in local markets for sale to no-option patients.

Timeline to Production

Hemostemix has agreed to transfer ACP to CytoImmune for production. The Company is financing to hire and train its onsite production staff. Combined they will produce 20 treatments per shift per month and build out ACTS.



The Offering

•Up to 50,000,000 Units, priced at $0.05

•Each Unit consists of one common share (a "Share") and one common share purchase warrant (a "Warrant"). Each warrant may be exercised at a price of $0.12 for a period of two years, subject to the accelerator described as follows: "If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the Closing Date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Exchange is greater than a weighted average price of **$0.15** per common share, the Company may provide notice in writing to the holders of the warrants by issuance of a press release that the expiry date of the warrants will be accelerated to the 30th day after the date on which the Company issues such press release."

•Minimum order: $5,000

•Securities issued subject to four month plus one day hold period.

•The offering is available to accredited investors and is RRSP/TFSA eligible.

USE OF PROCEEDS

•Proceeds from the Offering will be used to initiate sales and the processing of Initial batches in 2024-25, and for general working capital purposes.

NOTES:

1. CD1 – 5-yr secured (2nd position), due June- 2026, no remaining interest, converts at $0.40 per share.

2. CD2 – 5-yr secured (1st position), due April-2027, interest of 8% p.a. payable in shares, converts at $0.175 per share.

3. Warrants – Weighted average strike price $0.365, weighted average duration 20.6 months.

Cap Table

		MGT/INSIDER %
ISSUED AND OUTSTANDING:	87,122,318	16.5%
Shares for Interest – CD2[2]	2,229,616	89.1%
Warrants[3]	28,305,625	42.4%
Options	8,676,694	100%
PRE-FINANCING FULLY DILUTED (no CD Conversion)	126,334,253	31%
CD1[1]	6,250,000	100%
CD2[2]	15,714,286	89.1%
PRE-FINANCING FULLY DILUTED (with CD Conversion)	148,298,539	40.5%
CytoImmune's Subscription: Manufacturing Services Agreement	30,140,000	0%
Maximum Shares Issuable in Private Placement	50,000,000	5.76%
Maximum Warrants Issuable in Private Placement	50,000,000	5.76%
Maximum Broker Warrants Issuable	4,000,000	0%
POST-FINANCING FULLY DILUTED (with CD Conversion)	282,438,539	22.3%

5 Year Pro Forma

CAD $000s

Cash Use - Manufacturing and Required Operating Costs	Year 1	Year 2	Year 3	Year 4	Year 5
CytoImmune - Contract Mfg (Includes 22 Therapies for Sale)	675	676			
HEM Costs - Equipment, Testing/Certification, Lease costs	450	921	921	921	921
Hem Costs - People	300	1,200	1,200	1,200	1,200
Hem Costs - Transport; Direct variable costs +10%	143	2,191	2,340	2,340	2,340
Manufacturing Costs Subtotal	1,568	4,988	4,461	4,461	4,461
Sales Costs	110	1,348	1,440	1,440	1,440
Regulatory & Patents	340	120	120	120	120
Corporate	800	1,000	1,150	1,300	1,500
Other/Contingency	400	500	550	600	650
Subtotal of Corporate, Regulatory and Patents	1,650	2,968	3,260	3,460	3,710
Cash Used	3,218	7,956	7,721	7,921	8,171
Max Gross Corp Exp's eligible for Tax Credit	577	1,402	1,643	1,655	1,668
Production Information					
Capacity	30	450	480	480	480
Utilization Percentage	75%	75%	75%	75%	75%
Batches Sold	22	337	360	360	360
Cash Sources					
Equity for Contract	1,500				
Equity Financing of $2.5MM, net of 8%	2,300				
Therapies Revenue	1,100	16,850	18,000	18,000	18,000
Act 60 - Cash back (factored at 90%)		1,399	3,761	3,696	3,725
Cash Generated	4,900	18,249	21,761	21,696	21,725
Change in Cash - for the period	1,792	10,293	14,040	13,775	13,553
Cumulative cash available for debt service, trials, ACTS, W/C	1,792	12,085	26,124	39,899	53,452

Key Takeaways

ACP is a break-through treatment for no-option angina, dilated and ischemic cardiomyopathy and CLTI.

The Company will generate revenue from the early start of production and produce for sales to no-option patients at an 80% Margin.

The Company expects to be cashflow positive by late 2025.

ACT 60 generates 50% cash back of all R&D, a 15-year 4% profit tax, and a 20% tax credit for offshore expenses..

Management and the board have $8.7 million invested and own 38.8% of the equity.

CytoImmune provides the Company with a renewable two-year fixed cost, high margin, product to sell globally.

ACP is effective, and because it is sourced from the patient's blood and cultured in the patient's serum, it is completely autologous and therefore safe in the short term and the long term.

ACP is protected by 91 patents and is globally scalable.

The production team has more than 20 years of stem cell experience.

The Company has filed for orphan disease status for Dilated Cardiomyopathy.

HEMOSTEMIX

Dr. Ina Sarel

PhD, Chief Scientific Officer

Worked with the Company since 2008

Dr. Fraser Henderson

MD, Chief Medical Officer

Practicing Neurosurgeon

David Reese

BA, MBA - Former CEO

Senior Operating and Financial Consultant

Hiring PM in PR

Thomas Smeenk

BA President & CEO, Co-Founder

Co-managed and financed Hemostemix start-up 2006-2011

Peter Lacey

ICD.D, Chairman Founder

Chairman, CEO Cervus Corporation

Dr. Ronnie Hershman

M.D., F.C.C.S, Director

Practicing Cardiologist

Loran Swanberg

Director, Owner

Landsman properties Ltd.

HEMOSTEMIX

Dr. York Hsiang

Prof. Vascular Surgery

Univ. British Columbia

Dr. Alan Lumsden

Chair, Dept of Cardiology

Houston Methodist

Dr. Ernst Von Schwarz

UCLA, Cardiologist

Beverly Hills, California

Dr. Johannes Grillari

Associate Professor

Ludwig Boltzmann Institute
Vienna Austria

Dr. Pierre Leimgruber

Cardiologist & “Patient”

Former CMO, Hemostemix,
Seattle Washington

Dr. Norman Wong

Dept of Medicine, Dept of
Biochemistry & Molecular Biology

University of Alberta,
Calgary

Thank You!
Get in Touch

Thomas Smeenk, CEO, 905-580-4170
TSmeenk@Hemostemix.com
David Reese, 416-561-7245
DReese@Hemostemix.com